Biogen (NASDAQ:BIIB) had its buy rating reissued by analysts at Credit Suisse Group AG. They currently have a $384.00 price target on the stock.
ConforMIS (NASDAQ:CFMS) had its hold rating reiterated by analysts at Canaccord Genuity. The analysts wrote, “We recently had the opportunity to host a fireside chat with ConforMIS management as well as visit the company’s booth at AAOS. Overall, we came away incrementally positive on the opportunities ahead of ConforMIS and continue to think commercial momentum through the H1/18 could represent an inflection point in the business. Specifically, we think the commercial changes implemented mid-2017, including new leadership, sales rep hiring, and the build-out of a corporate accounts team position the company with the opportunity for increased productivity into the H2/18. From our recent meetings with management, we highlight additional clinical data that bolsters the company’s implant technology and a strong product pipeline that should support market momentum over the next several years.””
Columbus McKinnon (NASDAQ:CMCO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $42.00 price target on the stock. According to Zacks, “Columbus McKinnon, is a broad-line designer, manufacturer and supplier of sophisticated material handling products and integrated material handling solutions that are widely distributed to industrial and consumer markets worldwide. The Company’s material handling products are sold, omestically and internationally, principally to third party distributors and, to a lesser extent, directly to manufacturers and other end-users. The Company’s integrated material handling solutions businesses deal directly with end-users. “
ProShares UltraShort DJ-UBS Commodity (NYSEARCA:CMD) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $130.00 price target on the stock. According to Zacks, “Cantel Medical Corporation is a global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers, which improve outcomes and help save lives. Through an expansive portfolio of endoscopy, water purification and filtration, and healthcare disposables, Cantel Medical provides high-quality infection prevention solutions and unsurpassed service, touching millions of patients each year around the world. Cantel Medical is a leading provider of infection prevention products and services in the healthcare market. Cantel Medical specializing in the Endoscopy procedure disposables includes single-use valves and irrigation tubing. Medical device reprocessing systems, disinfectants, detergents and other supplies are used to disinfect high-level endoscopes. “
William Blair started coverage on shares of CNO Financial Group (NYSE:CNO). They issued a buy rating on the stock.
Crane (NYSE:CR) had its buy rating reiterated by analysts at Canaccord Genuity. They currently have a $110.00 target price on the stock. The analysts wrote, “We recently spent a day on the road with Crane management. While the company’s message remains consistent with the outlook provided at the recent investor day, we are confident in the potential upside from the Crane Currency acquisition, and believe the expected mid-teens EPS growth through 2021 will be a positive catalyst for the stock. Crane remains vulnerable to broader economic factors, but there appears to be little near-term risk associated with the steel and aluminum tariffs, based on what we know about the implementation, and the macro assumptions embedded in the 2018 guidance appear conservative. We like the Crane Currency acquisition, and believe that as management delivers on the earnings contribution from the acquisition (as well as the repositioning), we will see a steady improvement in investor sentiment. Much of the focus was on the timing of the Crane Currency integration.””
Credit Suisse Group (NYSE:CS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “CREDIT SUISSE GROUP and Winterthur offer investment products, private banking and financial advisory services, as well as insurance and pension solutions. Credit Suisse First Boston provides securities underwriting, sales and trading, financial advisory, investment research, venture capital and asset management services. Because they specialize in gaining a deep understanding of their clients’ financial needs, they know that no one’s needs are two-dimensional. 360° Choice. “
Caesarstone (NASDAQ:CSTE) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “CaesarStone Ltd manufactures engineered quartz surfaces for residential and commercial buildings as countertops, vanities, wall cladding, floors and other interior surfaces. The company’s product consists of Classico, Supernatural, Motivo and Concetto. CaesarStone Ltd, formerly known as Caesarstone Sdot-Yam Ltd., is based in MP Menashe, Israel. “
CytomX Therapeutics (NASDAQ:CTMX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. “
Cenovus Energy (NYSE:CVE) (TSE:CVE) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cenovus Energy Inc. is a Canadian integrated oil company. Operations include oil sands projects in northern Alberta, which use specialized methods to drill and pump the oil to the surface, and established natural gas and oil production in Alberta and British Columbia. The company also has 50% ownership in two U.S. refineries. “
CVR Refining (NYSE:CVRR) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “CVR Refining, LP is engaged in the refining of petroleum primarily in the United States. It has refining and related logistics assets that operate in the mid-continent region. The company operates in Coffeyville, Kansas, Wynnewood and Oklahoma. CVR Refining, LP is headquartered in Sugar Land, Texas. “
Darling Ingredients (NYSE:DAR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $21.00 price target on the stock. According to Zacks, “Darling Ingredients Inc. is a provider of rendering, cooking oil and bakery waste recycling and recovery solutions. It collects and transforms all aspects of animal by-product streams into broadly used and specialty ingredients, such as gelatin, edible fats, feed-grade fats, animal proteins and meals, plasma, pet food ingredients, organic fertilizers, yellow grease, fuel feedstock, green energy, natural casings and hides. The Company also provides grease trap services to food service establishments, environmental services to food processors and sells restaurant cooking oil delivery and collection equipment. Darling Ingredients Inc., formerly known as Darling International Inc., is headquartered in Irving, Texas. “
Despegar Com (NYSE:DESP) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Despegar.com, Corp. provides online travel booking services. The Company’s business segment consists of Air, as well as Packages, Hotels and Other Travel Products. It offers online hotels, car, flights, vacation rentals, packages, and ticket booking services. The company’s destinations include Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Spain, the United States, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Dominican Republic, Uruguay and Venezuela. Despegar.com, Corp. is based in Buenos Aires, Argentina. “
Del Frisco's Restaurant Group (NASDAQ:DFRG) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Del Frisco’s Restaurant Group, LLC develops, owns and operates three contemporary, complementary restaurant concepts: Del Frisco’s Double Eagle Steak House, Sullivan’s Steakhouse and Del Frisco’s Grille. The restaurants offer selections that include steaks, lobster tails, lamb chops and fresh seafood, as well as an extensive wine selection. Del Frisco’s Restaurant Group, LLC is headquartered in Wichita, Kansas. “
Erste Group Bank (OTCMKTS:EBKDY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $29.00 target price on the stock. According to Zacks, “The Erste Bank der Muster is a traditional banking group and providering financial services in Central and Eastern Europe. It focuses on retail and SME banking. It offers a range of products through group-wide bundling of product know how into Competence Centres covering, among others, Debt financing, Equity capital markets ,Mergers and acquisitions,Debt advisory, Project financing, Syndication, Real Estate financing and solutions, Infrastructure Finance & Public Sector, Merchant Banking / Private Equity, Leasing solutions (IMMORENT), and Corporate Cash Management. Its customers can avail its products in netbanking, wether it is Komfort-Kredit, Profit account, Bonus account, Building society contract, Pension plan or the order of MasterCard or VISA Card. Erste Bank focuses on private clients, corporate clients and the public sector. it offers all financial products under one roof. It operates in the areas of investment , construction and living , and leasing. Erste Bank is based in Vienna, Austria. “
Globus Medical (NYSE:GMED) had its buy rating reissued by analysts at Canaccord Genuity. They currently have a $53.00 target price on the stock. The analysts wrote, “We recently had the opportunity to host a fireside chat with Globus, as well as visit the company’s booth during the AAOS conference and came away incrementally more confident in the growth opportunities ahead of the company. Specifically, early feedback and success with the ExcelsiusGPS system reinforce our view that the robotic platform can provide a tailwind to an improving core US spine business. In trauma, we were encouraged by the early excitement around the initial product launches – including 6 recently cleared systems to complement the 5 launched at OTA back in October – which we expect to develop into a growth driver in 2019 and beyond. Net, net, while the valuation certainly reflects continued execution in 2018, we are increasingly optimistic that the improving fundamentals in the core US spine business, early success in robotics, and OUS momentum are capable of delivering continued upside to current guidance – thus supporting continued share appreciation.””
Kroger (NYSE:KR) was given a $27.00 price target by analysts at Morgan Stanley. The firm currently has a hold rating on the stock.
Lincoln Electric (NASDAQ:LECO) was upgraded by analysts at KeyCorp to an overweight rating.
Micron Technology (NASDAQ:MU) had its target price raised by Nomura. Nomura currently has a buy rating on the stock.
Micron Technology (NASDAQ:MU) had its target price boosted by Evercore ISI from $60.00 to $80.00. They currently have an outperform rating on the stock.
Rewalk Robotics (NASDAQ:RWLK) had its buy rating reaffirmed by analysts at Canaccord Genuity. Canaccord Genuity currently has a $2.00 price target on the stock. The analysts wrote, “We maintain our BUY rating on ReWalk Robotics following Q4/17 results. ReWalk reported revenues of $1.5M, below CG/consensus of $2.1M/$1.9M. Although the shipment of 23 systems was well below our expectation for 42 systems, ReWalk sales benefited from a favorable mix of system purchases and rental conversions in the quarter. Despite the weaker than anticipated system placements, we were encouraged to see another quarter of strong demand and another positive coverage decision with reimbursement through Italy’s worker’s compensation group. While commercial unit placements continue to be lumpy Q/Q we continue to view the broader pipeline (Restore soft suit for stroke) positively in the H2/18 and beyond. Positive momentum in demand and reimbursement decisions: In Q4/17 the company placed 23 total units, down from 39 Y/Y but up Q/Q from 16.””
Sarepta Therapeutics (NASDAQ:SRPT) had its hold rating reissued by analysts at Credit Suisse Group AG. Credit Suisse Group AG currently has a $81.00 target price on the stock.
Trevena (NASDAQ:TRVN) was given a $5.00 target price by analysts at Oppenheimer Holdings Inc.. The firm currently has a buy rating on the stock.
Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.